

Soligenix Inc (SNGX) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/S38783FE0CDEN.html>

Date: September 2021

Pages: 55

Price: US\$ 125.00 (Single User License)

ID: S38783FE0CDEN

Abstracts

Soligenix Inc (SNGX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Soligenix Inc (Soligenix) is a late-stage biopharmaceutical company which focuses on the development and commercialization of products for the treatment of rare diseases and unmet medical needs. It develops specialized biotherapeutics for the treatment of orphan diseases such as cutaneous T-cell lymphoma, pediatric Crohn's disease, oral mucositis and acute radiation enteritis. It develops proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the treatment of gastrointestinal disorders that are characterized by high inflammation. The company has active development programs for RiVax, a ricin toxin vaccine; and SGX943 for infectious disease. These vaccine programs are supported by ThermoVax, a heat stabilization technology. Soligenix is headquartered in Princeton, New Jersey, the US.

Soligenix Inc Key Recent Developments

Aug 13,2021: Soligenix Announces Recent Accomplishments And Second Quarter 2021 Financial Results

May 17,2021: Soligenix Announces Recent Accomplishments And First Quarter 2021 Financial Results

Apr 13,2021: Soligenix Announces Presentations at Prominent Scientific Conferences

Mar 30,2021: Soligenix Announces Recent Accomplishments and Year-End 2020

Financial Results

Mar 09,2021: Soligenix to receive \$865,000 in non-dilutive funding through New Jersey technology business tax certificate transfer program

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

- Soligenix Inc - Key Facts
- Soligenix Inc - Key Employees
- Soligenix Inc - Key Employee Biographies
- Soligenix Inc - Major Products and Services
- Soligenix Inc - History
- Soligenix Inc - Company Statement
- Soligenix Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

- Company Overview
- Soligenix Inc - Business Description
- Business Segment: Public Health Solutions Segment
- Overview
- Performance
- Business Segment: Specialized BioTherapeutics Segment
- Overview
- Performance
- Soligenix Inc - Corporate Strategy
- Soligenix Inc - SWOT Analysis
- SWOT Analysis - Overview
- Soligenix Inc - Strengths
- Soligenix Inc - Weaknesses
- Soligenix Inc - Opportunities
- Soligenix Inc - Threats
- Soligenix Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Soligenix Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 13, 2021: Soligenix Announces Recent Accomplishments And Second Quarter 2021 Financial Results

May 17, 2021: Soligenix Announces Recent Accomplishments And First Quarter 2021 Financial Results

Apr 13, 2021: Soligenix Announces Presentations at Prominent Scientific Conferences

Mar 30, 2021: Soligenix Announces Recent Accomplishments and Year-End 2020 Financial Results

Mar 09, 2021: Soligenix to receive \$865,000 in non-dilutive funding through New Jersey technology business tax certificate transfer program

Feb 11, 2021: Soligenix to Present at the 2021 BIO CEO & Investor Digital Conference

Nov 12, 2020: Soligenix announces recent accomplishments and third quarter 2020 financial results

Sep 15, 2020: Soligenix announces publication demonstrating thermostabilization of filovirus vaccine antigens

Aug 14, 2020: Soligenix announces recent accomplishments and second quarter 2020 financial results

Jul 20, 2020: Soligenix issues corporate update - highlights important catalysts for second half of 2020

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Soligenix Inc, Key Facts
Soligenix Inc, Key Employees
Soligenix Inc, Key Employee Biographies
Soligenix Inc, Major Products and Services
Soligenix Inc, History
Soligenix Inc, Subsidiaries
Soligenix Inc, Key Competitors
Soligenix Inc, Ratios based on current share price
Soligenix Inc, Annual Ratios
Soligenix Inc, Annual Ratios (Cont...1)
Soligenix Inc, Interim Ratios
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Soligenix Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Soligenix Inc, Performance Chart (2016 - 2020)

Soligenix Inc, Ratio Charts

Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Soligenix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Soligenix Inc (SNGX) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/S38783FE0CDEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S38783FE0CDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970